Epidemiology of Use of Novel Psychoactive Substances

Novel Psychoactive Substances: Classification, Pharmacology and Toxicology

Volumn , Issue , 2013, Pages 79-103

  Sumnall, Harry ^a   McVeigh, James ^a   Evans Brown, Michael J ^a,b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Epidemiology; Hallucinogens; Legal highs; Mephedrone; Novel psychoactive drugs; Psychostimulants

Indexed keywords

EID: 84903808039     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415816-0.00004-3     Document Type: Chapter

References (105)

1. Wasso RG Notes on the present status of ololiuhqui and the other hallucinogens of Mexico 1962, 20. Botanical Museum Leaflets, Harvard University, p. 161-212.
2. Sumnall HR, Measham F, Brandt SD, Cole JC Salvia divinorum use and phenomenology: results from an online survey. J Psychopharmacol 2011, 25:1496-1550.
3. Lange JE, Daniel J, Homer K, Reed MB, Clapp JD Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend 2010, 108:138-140.
4. Kjellgren A, Soussana C Heaven and hell - a phenomenological study of recreational use of 4-HO-MET in Sweden. J Psychoactive Drugs 2011, 43:211-219.
5. Baron M, Elie M, Elie L An analysis of legal highs-do they contain what it says on the tin?. Drug Test Anal 2011, 3:576-581.
6. Brandt SD, Sumnall HR, Measham F, Cole JC The confusing case of NRG-1. BMJ 2010 Jul 6, 341:c3564.
7. Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, et al. Purchasing 'legal highs' on the Internet is there consistency in what you get?. QJM 2010, 103:489-493.
8. Measham F, Moore K, Østergaard J Mephedrone, 'Bubble'' and unidentified white powders: the contested identities of synthetic 'legal highs'. Drugs Alcohol Today 2011, 11:137-146.
9. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE Monitoring the Future national results on adolescent drug use: overview of key findings, 2011 2012, Institute for Social Research, The University of Michigan, Ann Arbor.
10. Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T The ESPAD report 2007: alcohol and other drug use among students in 35 European countries 2009, Swedish Council for Information on Alcohol and Other Drugs (CAN), Stockholm.
11. Substance Abuse and Mental Health Services Administration Results from the 2010 National survey on drug use and health: summary of national findings 2011, Substance Abuse and Mental Health Services Administration, Rockville, MD.
12. Substance Abuse and Mental Health Services Administration, Office of Applied Studies The NSDUH report - Use of specific hallucinogens: 2006 2008, Substance Abuse and Mental Health Services Administration, Rockville, MD.
13. Smith K, Flatley J Drug misuse declared; findings from the 2010/11 British Crime Survey 2011, Home Office, London.
14. Home Office Statistics 2012 Drug misuse declared; findings from the 2011/12 crime survey for England and wales. Available: <>[accessed 26.07.12]. http://www.homeoffice.gov.uk/publications/science-research-statistics/research-statistics/crime-research/drugs-misuse-dec-1112/.
15. Bird S More insights on mephedrone from british crime survey. Straight Statistics Blog 2011, Available: [accessed 09.02.12].
16. Brunt T, Rigter S, Hoek J, Vogels N, VanDijk P, Niensk R An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants. Addiction 2009, 104:798-805.
17. Brunt T, Poortman A, Niesink R, Van den Brink W Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2011, 25:1543-1547.
18. Carhart-Harris R, King L, Nutt D A web-based survey on mephedrone. Drug Alcohol Depend 2011, 118:19-22.
19. Sumnall HR, McVeigh J, Evans-Brown MJ Social, policy, and public health perspectives on new psychoactive substances. Drug Test Anal 2011, 3:515-523.
20. Measham F, Moore K Repertoires of distinction: exploring patterns of weekend polydrug use within local leisure scenes across the English night time economy. Criminol Crim Justice 2009, 9:437-464.
21. National Advisory Committee on Drugs (NACD) and Public Health Information and Research Branch (PHIRB) Drug use in Ireland and Northern Ireland: first results from the 2010/11 drug prevalence survey 2011, NACD & PHIRB, Dublin.
22. Mixmag. Mixmag survey 2010. Available: <>; 2010 [accessed 08.02.12]. http://www.mixmag.net/words/news/the-mixmag-drug-survey-launches.
23. Mixmag. Mixmag survey 2011. Available: <>; 2011 [accessed 08.02.12]. http://www.mixmag.net/words/news/the-mixmag-drug-survey-launches.
24. Kelleher C, Christie R, Lalor K, Fox J, Bowden M, O'Donnell C An overview of new psychoactive substances and the outlets supplying them 2011, NACD, Dublin.
25. Global drugs survey 2012. Available: <>[accessed 20.07.12]. http://www.globaldrugsurvey.com/.
26. Bruno R, Matthews AJ, Dunn M, Alati R, McIlwraith F, Hickey S, et al. Emerging psychoactive substance use among regular ecstasy users in Australia. Drug Alcohol Depend. 2011, 10.1016/j.drugalcdep.2011.11.020.
27. Wood DM, Hunter L, Measham F, Dargan PI Limited use of novel psychoactive substances in South London nightclubs. Q J Med. 2012, Advance Access published 19/6/12. 10.1093/qjmed/hcs107.
28. Measham F, Wood D, Dargan P, Moore K The rise in legal highs: prevalence and patterns in the use of illegal drugs and first and second generation 'legal highs' in south London gay dance clubs. J Subst Use 2011, 16:263-272.
29. Dargan PI, Albert S, Wood DM Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103:875-879.
30. Werse B, Müller O Spice, smoke, sence & co. - smoking mixtures containing cannabinoids: consumption and motivation for consumption against the backdrop of changing laws 2010, Centre for Drug Research, Frankfurt, English summary available: [accessed 08.02.12].
31. Khey DN, Miller BL, Griffin OH Salvia divinorum use among a college student sample. J Drug Educ 2008, 38:297-306.
32. Miller BL, Griffin OH, Gibson GL, Khey DN Trippin' on Sally D: exploring predictors of Salvia divinorum experimentation. J Crim Justice 2009, 37:396-403.
33. Topp L, Breen C, Kaye S, Darke S Adapting the illicit drug reporting system (IDRS) to examine the feasibility of monitoring trends in the markets for 'party drugs'. Drug Alcohol Depend 2004, 73:189-197.
34. Sindicich N, Burns L Australian trends in ecstasy and related drug markets 2010: findings from the ecstasy and related drugs reporting system (EDRS) 2011, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
35. Beddoes D, Sheikh S, Pralat R, Sloman J The impact of drugs on different minority groups; a review of UK literature. Part 2: lesbian, gay, bisexual and transgender (LGBT) groups 2010, UKDPC, London.
36. Evans-Brown MJ, McVeigh J Anabolic steroid use in the general population of the United Kingdom. Elite sport, doping and public health 2009, 75-97. University of Southern Denmark Press, Odense. V. Møller, P. Dimeo, M. McNamee (Eds.).
37. Evans-Brown M, Kimergård A, McVeigh J Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market. Drug Test Anal 2009, 1:323-326.
38. Assael S Steroid nation 2007, ESPN Books, Venice beach, CA.
39. Takahashi Y, Kipnis DM, Daughaday WH Growth hormone secretion during sleep. J Clin Invest 1968, 47:2079-2090.
40. Luby S, Jones J, Zalewski A GHB use in South Carolina. Am J Public Health 1992, 82:128.
41. Oyama T, Takiguchi M Effects of gamma-hydroxybutyrate and surgery on plasma human growth hormone and insulin levels. Agressologie 1970, 11:289-298.
42. Chin MY, Kreutzer RA, Dyer JE Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992, 156:380-384.
43. Philen RM, Ortiz DI, Auerbach SB, Falk H Survey of advertising for nutritional supplements in health and bodybuilding magazines. J Am Med Assoc 1992, 268:1008-1011.
44. Dyer JE γ-Hydroxybutyrate: a health-food product producing coma and seizure like activity. Am J Emerg Med 1991, 9:321-324.
45. Krawczeniuk A The occurrence of gamma-hydroxybutyric acid (GHB) in a steroid seizure. Microgram 1993, 26:160-166.
46. Steele MT, Watson WA Acute poisoning from gamma hydroxybutyrate (GHB). Mo Med 1995, 92:354-357.
47. Myrenfors P Ten cases of poisoning with gamma hydroxybutyrate. An endogenous substance used by body builders. Lakartidningen 1996, 93:1973-1974.
48. Burton C Anabolic steroid use among the gym population in Clwyd. Pharm J 1996, 256:557-559.
49. Klatz R, Kahn C Grow young with HGH 1998, HarperCollins, New York.
50. Medicines Control Agency Mail. The MCA updating service. 2000;118 (March/April): 1-31.
51. Medicines Control Agency Mail. The MCA updating service. 2001;128 (Nov/Dec): 1-26.
52. Medicines Control Agency Mail. The MCA updating service. 2003;135 (Jan/Feb): 1-25.
53. EMCDDA Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs 2002, Office for Official Publications of the European Communities, Luxembourg.
54. EMCDDA, and Europol 2011 EMCDDA-Europol 2010 annual report on the implementation of Council Decision 2005/387/JHA. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
55. Bailey DJ, O'Hagan D, Tavasli M A short synthesis of (S)-2-(diphenylmethyl)pyrrolidine, a chiral solvating agent for NMR analysis. Tetrahedron: Asymmetry 2003, 8:149-153.
56. Van Hout MC, Bingham T A costly turn on: patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy 2012, 23:188-197.
57. Deehan A, Saville E Calculating the risk: recreational drug use among clubbers in the South East of England 2003, Home Office, London.
58. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
59. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2011, 28:686-689.
60. Dunn M, Degenhardt L, Bruno R Transition to and from injecting drug use among regular ecstasy users. Addict Behav 2010, 35:909-912.
61. Topp L, Hando J, Dillon P, Roche A, Solowij N Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999, 55:105-115.
62. The United Nations Office on Drugs and Crime Synthetic cannabinoid receptor agonists in herbal products 2011, UNODC, Geneva.
63. Dresen S, Kneisel S, Weinmann W, Zimmermann R, Auwärter V Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoid receptor agonists of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom 2011, 46:163-171.
64. Vandrey R, Dunn KE, Fry JA, Girling ER A survey study to characterise use of Spice products (synthetic cannabinoid receptor agonists). Drug Alcohol Depend 2012, 120:238-241.
65. Office for National Statistics Internet access quarterly update 2011 Q2 2011, ONS, London.
66. Perron BE, Ahmedani BK, Vaughn MG, Glass JE Use of salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abuse 2011, 1-6. Early Online.
67. Wu L-T, Woody GE, Chongming Y, Li J-H, Blazer DG Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2011, 2:53-68.
68. Ford JA, Watkins WC, Blumenstein L Correlates of Salvia divinorum use in a national sample: findings from the 2009 national survey on drug use and health. Addict Behav 2011, 36:1032-1037.
69. Akers R Deviant behavior: a social learning approach 1985, Wadsworth, Belmont, CA.
70. Raymond JS Behavioral epidemiology: the science of health promotion. Health Promot 1989, 4:281-286.
71. Sallis JF, Owen N, Fotheringham MJ Behavioral epidemiology: a systematic framework to classify phases of research on health promotion and disease prevention. Ann Behav Med 2000, 22:294-298.
72. Perry CL, Murray DM The prevention of adolescent drug abuse: implications from etiological, developmental, behavioral, and environmental models. J Prim Prev 1985, 6:31-52.
73. Galea S, Nandi A, Vlahov D The social epidemiology of substance use. Epidemiol Rev 2004, 26:36-52.
74. Gallup 2011 Youth Attitudes on Drugs. Analytical report. Flash barometer 330. Brussels: European Commission.
75. Baggot MJ, Erowid E, Erowid F, Galloway GP, Mendelson J Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend 2010, 111:250-256.
76. Health Protection Agency (HPA) National poisons information service - annual report 2010/2011 2011, HPA, London.
77. EMCDDA Guidelines for the prevalence of problem drug use (PDU) key indicator at national level 2004, Office for Official Publications of the European Communities, Luxembourg.
78. Schmidt MM, Sharma A, Schifano F, Feinmann C Legal highs on the net-evaluation of UK-based websites, products and product information. Forensic Sci Int 2011, 206:92-97.
79. Birdwell J, Chapman J, Singleton N Taking drugs seriously: a demos and UK drug policy commission report on legal highs 2010, UKDPC, London, UK.
80. United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality 2011 Drug Abuse Warning Network (DAWN), 2009 [Computer file ICPSR31921-v1] Ann Arbor, MI: Inter-university Consortium for Political and Social Research.
81. Reuter P Options for regulating new psychoactive drugs: a review of recent experiences and an analytic framework 2011, UK Drug Policy Commission, London.
82. Bronstein AC, Spyker DA, Cantilena LR, Green JL Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th annual report. Clin Toxicol 2011, 49:910-941.
83. American Association of Poison Control Centers Fake marijuana spurs more than 2500 calls to US poison centers this year alone 2010, American Association of Poison Control Centers, Alexandria, VA.
84. Toth AR, Hideg Z, Institoris L Mephedrone - an old-new drug of abuse. Orv Hetil 2011, 152:1192-1196.
85. MacKellar D, Valleroy L, Karon J, Lemp G, Janssen R The young men's survey: methods for estimating HIV seroprevalence and risk factors among young men who have sex with men. Public Health Rep 2006, 11:138-144.
86. Muhib FB, Lin LS, Stueve A, Ford WL, Miller RL, Johnson WD Avenue-based method for sampling hard-to-reach populations. Public Health Rep 2001, 116:216-222.
87. Stueve A, O'Donnell L, Duran R, Sandoval A, Blome J Time-space sampling in minority communities: results with young Latino men who have sex with men. Am J Public Health 2001, 91:922-926.
88. Semaan S Time-space sampling and respondent-driven sampling with hard-to-reach populations. Methodol Innov Online 2010, 5:60-75.
89. Parsons JT, Grov C, Kelly BC Comparing the effectiveness of two forms of time space sampling to identify club drug-using young adults. J Drug 2008, 38:1061-1801.
90. Ramo DE, Grov C, Delucchi K, Kelly BC, Parsons JT Typology of club drug use among young adults recruited using time-space sampling. Drug Alcohol Depend 2010, 107:119-127.
91. Boeri M, Sterk C, Elifson K Rolling beyond raves: ecstasy use outside the rave setting. J Drug 2004, 34:831-860.
92. Fendrich M, Wislar JS, Johnson TP, Hubbell A A contextual profile of club drug use among adults in Chicago. Addiction 2003, 98:1693-1703.
93. Heckathorn DD, Jeffri J Finding the beat: using respondent driven sampling to study jazz musicians. Poetics 2001, 28:307-329.
94. Wejnert C, Heckathorn D Web-based network sampling: efficiency and efficacy of respondent-driven sampling for online research. Sociol Methods Res 2008, 37:105-134.
95. Goela S, Salganik MJ Assessing respondent-driven sampling. PNAS 2010, 107:6743-6747.
96. Petróczi A, Nepusz T, Cross P, Taft H, Shah S, Deshmukh N, et al. New non-randomised model to assess the prevalence of discriminating behaviour: a pilot study on mephedrone. Subst Abuse Treat Prev Policy 2011, 6:20.
97. Archer JRH, Dargan PI, Rintoul-Hoad S, Hudson S, Wood DM Using urinals in the night-time economy to determine what recreational drugs people are actually using. Br J Clin Pharmacol 2012, 73:985.
98. Daughton CG Illicit drugs: contaminants in the environment and utility in forensic epidemiology. Rev Environ Contam Toxicol 2011, 210:59-110.
99. EMCDDA Assessing illicit drugs in wastewater 2008, Office for Official Publications of the European Communities, Luxembourg.
100. van Nuijs ALN, Castiglioni S, Tarcomnicu I, et al. Illicit drug consumption estimations derived from wastewater analysis: a critical review. Sci Total Environ 2011, 409:3564-3577.
101. Schroeder HF, Gebhardt W, Thevis M Anabolic doping, and lifestyle drugs, and selected metabolites in wastewater - detection, quantification, and behaviour monitored by high resolution MS and MS before and after sewage treatment. Anal Bioanal Chem 2010, 398:1207-1229.
102. Zuccato E, Chiabrando C, Castiglioni S, Bagnati R, Fanelli R Estimating community drug abuse by wastewater analysis. Environ Health Perspect 2011, 116:1027-1032.
103. Cecinato A, Balducci C, Guerriero E, Sprovieri F, Cofone F Possible social relevance of illicit psychotropic substances present in the atmosphere. Sci Total Environ 2011 2011, 412-413:87-92.
104. Bates C Cash-strapped young adults turning to cheaper 'bubble' drugs following mephedrone ban. Dly Mail 2011, Nov 8. Available from: .
105. Butler P Drug use survey: tell us what you take. Guardian 2011, Nov 23. Available from: .